Targeted Therapies
 /  Targeted Therapies

Some patients have a mutation in the protein called BRAFV600 which can cause the cell to grow in an uncontrolled manner, resulting in the formation of a tumour. Targeted therapies can be used to block uncontrolled signals and slow down the rate of tumour growth.

Tafinlar (dabrafenib) and Mekinist (trametinib)

Tafinlar and Mekinist are treatments used in combination for those with the BRAFV600 mutation.
They are both protein inhibitors and target the pathways that allow tumour growth, slowing down cell growth and division.

Tafinlar and Mekinist used in combination form a double blockade and the combination of the two inhibitors (BRAF inhibitor and MEK inhibitor) has shown significantly improved survival and delayed drug resistance over the use of a single agent.

This treatment combination is taken orally (in pill form) each day.

Tafinlar and Mekinist can cause side effects. The most common side effects include fever,diarrhoea, nausea, vomiting, skin rash, swelling of ankles or feet and eye problems.

The combination of Tafinlar and Mekinist is listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of BRAFV600 mutation-positive unresectable metastatic melanoma.

Zelboraf (vemurafenib) and Cotellic (cobimetinib)

Zelboraf and Cotellic are treatments used in combination for those with the BRAFV600 mutation.
They are both protein inhibitors and target the pathways that allow tumour growth, slowing down cell growth and division.

Zelboraf and Cotellic used in combination form a double blockade and the combination of the two inhibitors (BRAF inhibitor and MEK inhibitor) has shown significantly improved survival and delayed drug resistance over the use of a single agent.

This treatment combination is taken orally (in pill form) each day.

Zelboraf and Cotellic can cause side effects. The most common side effects include sunburn or sun sensitivity, Cutaneous Squamous Cell Carcinoma (lesions) skin rash, blistering, swelling of the face, hands, or soles of the feet, joint discomfort and eye problems.

The combination of Zelboraf and Cotellic is not listed on the PBS

Stay Connected

Melanoma Patients Australia Ltd shared their post. ... See MoreSee Less

Are you still planning to attend MPA's Cairns melanoma forum? Please note bookings close today. Any questions, call us 1300 88 44 50

View on Facebook

The 'booty' just keeps on growing for our MPA Gala Dinner on 9 June. Buy your tickets at mpagaladinner2017.eventbrite.com/ and on the night you could be taking home a Soleil Pool Bar Signature Garden Tea for 6 thanks to Rydges Hotels & Resorts, cinema space for 24 at Blue Room Cinebar, a Henry Coughlin Photography experience & print or 4 passes for 9 holes at Holey Moley Golf Club (pic below).

Don't miss out on an arresting night of fun!
... See MoreSee Less

View on Facebook

This year's Palliative Care week theme is 'You matter, Your care matters. Palliative care can make a difference’.
So many of us confuse palliative care with end of life care, assuming that death is imminent if we are referred to palliative care. Palliative care embodies wholeness, peacefulness and enhanced quality of life-- pain and symptom management so that you can get on with living as well as you can until you can't. Whether this is for a day, a week or a year is irrelevant compared with the relief found when you can let go of fear and despair even for just 1 hour. Please call MPA 1300 88 44 50 in office hours for more information. #npcw
... See MoreSee Less

View on Facebook

Contact us

Head Office:
Level 8, East Wing
Wesley Research Institute
451 Coronation Dve, Auchenflower QLD 4066
PO Box 1771
Toowong BC QLD 4066

Phone: 1300 884 450
Mail: info@melanomapatients.org.au

Newsletter